Johns Hopkins cancer treatment spinout launches with $150M in funding

The Johns Hopkins University professor behind several Baltimore companies that have sold for hundreds of millions of dollars is launching a new venture to treat cancer, but this one is based outside the city. Hopkins cancer geneticist Bert Vogelstein’s new firm, Clasp Therapeutics, launched Wednesday morning with $150 million in financing led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, with participation from other health-focused investors such as the investment arm of Baltimore’s BlackBird Labs.